Bacterial delivery of phosphatase antagonists to metastatic breast cancer
Ended Project Grant Awarded Last action
- Award ID
- R43CA233136
- Recipient
-
Ernest Pharmaceuticals, Inc. UEI MKSZL7C5T1G5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $217,089
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding
-
- $223,593.70 Federal
- -$6,505.00 Non-federal
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $6,505 | $0 | |
| Amendment | $6,505 | $0 | |
| Amendment | -$6,505 | $0 | |
| Amendment | -$6,505 | -$6,505 | |
| Amendment | $0 | $0 | |
| Original award | $223,594 | $0 |
Quick answers
Who received award R43CA233136?
R43CA233136 was awarded to Ernest Pharmaceuticals, Inc. by National Cancer Institute (National Institutes of Health) on September 6, 2018.
How much is award R43CA233136 worth?
$217,089 has been obligated on R43CA233136: $223,594 in federal funding and -$6,505 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award